LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 26 Oct 2017 Planned End Date changed from 1 Jun 2018 to 1 Jan 2020.
- 26 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Jan 2018.
- 26 Oct 2017 Status changed from recruiting to active, no longer recruiting.